Medical device manufacturer Bedfont Scientific will launch its new and improved FeNO monitor exclusively at the world’s largest European Respiratory Society (ERS) Congress.
The second-generation family company has specialised in breath analysis for more than 40 years and will launch its 2nd generation NObreath® next week at the ERS Congress in Paris.
The device is being launched after the recent publication of the NICE guidance on Asthma: diagnosis, monitoring and chronic asthma management, to improve asthma care, which included the NObreath FeNO monitor from Bedfont as a recommended device.
To celebrate the exclusive launch, Bedfont will also be holding a competition at their stand where delegates will have the chance to be entered into a prize draw to win a new NObreath.
Jason Smith, Managing Director, commented, “As a breath analysis medical device manufacturer who exports globally, ERS is a key congress for us to reconnect with our customers from around the world.”
“We are thrilled to be launching the 2nd generation NObreath exclusively at ERS this year as we feel it would be quite symbolic; this launch will bring the product full circle, as the very first NObreath was too launched at an ERS Congress 11 years ago. We’re excited to show our customers what’s in store for the advancement of respiratory care.”
The ERS Congress take place from 15th to 19th September at the Paris Expo Porte de Versailles, Paris.